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Title: Doping in Sport: A review of medical practitioners’ knowledge, attitudes and 
beliefs 
 
 
 
Abstract 
 
Background: Central to the work of many medical practitioners is the provision of 
pharmaceutical support for patients. Patients can include athletes who are subject to anti-
doping rules and regulations which prohibit the use of certain substances in and out of 
competition. This paper examines the evidence on medical practitioners’ knowledge, attitudes 
and beliefs towards doping in sport. Methods: A systematic search strategy was followed. 
Research questions and relevance criteria were developed a priori. Potentially relevant studies 
were located through electronic and hand searches limited to English language articles 
published between 1990 and 2010. Articles were assessed for relevance by two independent 
assessors and the results of selected studies were abstracted and synthesised. Outcomes of 
interest were knowledge, attitudes and beliefs in relation to doping in sport. Results: Six 
studies met the inclusion criteria and were examined in detail. Samples reflected a range of 
medical practitioners drawn from the UK, France (2), Greece, Italy and Ireland. The 
investigations varied with respect to outcome focus and quality of evidence presented. 
Conclusion: While the extant empirical research posits a negative attitude towards illegal 
performance enhancement combined with a positive inclination towards doping prevention, it 
also exposes a limited knowledge of anti-doping rules and regulations. Insufficient education, 
leading to a lack of awareness and understanding, could render this professional group at risk 
of doping offences considering Article 2.8 of the World Anti-Doping Agency Code (WADC). 
Moreover, in light of the incongruence between professional medical codes and WADC 
Article 2.8, medical professionals may face doping dilemmas and therefore further discourse 
is required. At present, the current evidence-base makes it difficult to plan developmentally 
appropriate education to span the exposure spectrum. Addressing this situation appears 
warranted.  
 
Key words: Doping in Sports; Performance enhancing substances; Health; Sports Medicine; 
Medical Professionals  
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Introduction 
Providing pharmaceutical support for patients is central to the work of many medical 
practitioners from general practitioners to pharmacists.  Indeed, the exact style of 
prescription, together with the intensity of the recommendation to take such treatment, not 
only characterises the professional identity of the practitioner (Friedson, 1970) but also 
influences patient responsiveness and adherence (Armstrong, 2002). In this context, and 
notwithstanding the need to meet conventions for prescribing, professional variability is a 
strong indicator of professional autonomy (Armstrong, Reyburn, & Jones, 1996). It is also 
important to recognise that the variability in medical practitioner’s decision-making is often 
based on a lack of ‘gold standard’ evidence (Baiardini, Braido, Bonini, Compalati, & 
Canonica, 2009). Further, individual practitioners’ may be motivated to resist the unwanted 
influence that guidelines may have on the practitioner-patient relationship (Martin, 2003). 
The status of practitioners’ involvement in prescribing and administering performance 
enhancing drugs is at least contentious.  On the one hand, the goal of sports medicine 
includes human performance enhancement above normal functioning (Edwards & McNamee, 
2006).  However, this act alone challenges sporting ethics but is further problematic when 
these same substances also bring potentially harmful side-effects
1
.  Indeed, drug-supportive 
practitioners can point to recent criticisms of doping prevention programmes for their lack of 
focus on the safety of participants (Savulescu, Foddy, & Clayton, 2004; Waddington, 2001). 
In contrast, doctors might wrongly imagine that drugs users uniformly place great trust in 
them to provide accurate up-to-date information and to provide reliable supplies of quality-
assured drugs (Pope, Kanayama, Ionescu-Pioggia, & Hudson, 2004).  Moreover, Kanayama 
and colleagues (2010) assert that the failure of the scientific and medical communities to 
                                                 
1
 We also recognise that medical practitioners may deal with medications that contain active ingredients with 
greater harm potential than those found in banned performance enhancing substances. 
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recognise the efficacy of anabolic steroid use could explain the reluctance of steroid users to 
engage with medical practitioners in relation to such use (Dawson, 2001). Therefore, it is 
realistic to assume that an athlete might consult with a medical practitioner to monitor 
markers of health, rather than to validate the use of the drug per se. Collectively, these issues 
have been summarised in the phrase; ‘a counsel of perfection thwarted by reality’ (Collier, 
1988). 
Even though drug provision to athletes may be contrary to sporting, medical or even 
national legislation, it persists. Further this behaviour persists in spite of the risks associated 
with taking some of these performance-enhancing drugs (Garnier, 2006). This highlights the 
complexity of practitioner decision-making, which also involves managing the risks 
associated with more conventional drug-based treatments in the same athlete. However, the 
scale and nature of medical practitioner involvement in doping in sport remains unclear.  
Moreover, McNamee and Phillips (2010) clearly articulate the tensions that arise from the 
incongruence between the World Anti-Doping Agency Code (WADC) and medical 
professional codes, particularly in relation to confidentiality and disclosure. Until these issues 
are clarified the exact nature of the prescribing ‘problem’ and any associated ‘solution’ will 
also remain elusive.   
While numerous studies have attempted to quantify the extent of doping in sport 
(Waddington, Malcolm, Roderick, & Naik, 2005), or considered athletes doping social-
cognitions (Petroczi, 2007), literature regarding the attitudes, beliefs and knowledge of 
medical practitioners and support staff is limited.  Under the WADC, support staff may be 
charged with a doping offence if they are deemed to administer or attempt to administer any 
prohibited substance or method to any athlete in competition or out-of-competition or “assist, 
encourage, aid, abet, cover up or engage in any other type of complicity involving an anti-
doping rule violation” (WADA, 2009 p 25). Thus, it is important to interrogate the social 
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science doping literature that focuses on these support staff and on the sports anti-doping 
landscape. Therefore, this paper aims to amalgamate current literature and provide 
indications for the future direction of this area of research. 
 
Methods 
A comprehensive search was carried out and a set of relevance criteria developed a 
priori. To be included a paper needed to focus on medical practitioners and contain one or 
more of the following outcome measures: a) knowledge of doping and/or doping controls in 
sport, and b) attitudes and beliefs towards doping in sport. Studies that only reported 
prevalence rates or that made no specific reference to doping in sport were excluded.  
An electronic search strategy was developed using a series of doping related 
keywords to extract potentially relevant articles from a number of electronic databases: 
Medline (and Pubmed), PsycINFO, CINAHL, SPORTdiscus, Ingenta, Web of Science and 
ZETOC. Since each database has its own indexing terms bespoke search strategies were 
developed. The primary search terms included variations on the nomenclature of “doping”, 
“sport”, “medical practitioner”, “attitudes”, “beliefs” and “knowledge”. Only full papers 
published in peer reviewed journals in the English Language since 1990 were included.  
Papers were reviewed first by title, then by abstract, to determine inclusion. One 
member of the research team screened each citation in the master list, including the abstract 
(when available) to assess whether it examined medical practitioners, attitudes, knowledge 
and/or beliefs towards doping in sport. Articles that met these broad criteria were obtained for 
assessment by a second reviewer. Additional sources (e.g., reference lists of all articles 
deemed relevant) were also hand searched to identify studies not captured in the electronic 
searches.  
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Results 
The electronic search identified 53 potentially relevant articles. Two additional 
articles were identified through hand searching. Of these 55 articles, only six met the 
relevance criteria (Table 1). Of these six articles, the average response rate was 59% and 
study sample sizes ranged from 102 (Scarpino, et al., 1990) to 771 (Woods & Moynihan, 
2009). Two studies originated in France (2003) (Laure & Kriebitzsch-Lejeune, 2000) and the 
remaining studies emerged from the UK (Greenway & Greenway, 1997), Italy (Scarpino, et 
al., 1990), Greece (Panagiotis, Ourania, Christos, & Jannis, 2006) and Ireland (Woods & 
Moynihan, 2009).  In terms of samples, general practitioners (GPs) were the focus of most 
surveys (Greenway & Greenway, 1997; Laure, et al., 2003; Panagiotis, et al., 2006; Woods & 
Moynihan, 2009), males represented an average of 68% of respondents and the mean age of 
the participants across the studies was 41 years.  
 
 
The role of medical practitioners in anti-doping 
Self-reports showed a consensus among medical practitioners that they have a role to 
play in doping preventions. Specifically, 92% and 89% (Laure, et al., 2003; Woods & 
Moynihan, 2009) of GPs and 91% of retail pharmacists (Laure & Kriebitzsch-Lejeune, 2000) 
agreed with this proposition. A monitoring function was also highlighted; 10% of Irish GPs, 
declared a willingness to monitor the athlete during prohibited substance use (Woods & 
Moynihan, 2009). Furthermore, 27% declared they would refer the athlete to another 
practitioner for a prescription or for monitoring.   
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Table 1. Articles included in this review. 
 
 
Authors 
 
 
Country 
 
Sample 
 
Design & methods 
 
Study results 
 
Scarpino et 
al., (1990) 
 
 
 
Italy 
 
 
102 doctors (part of a larger 
study with a total n=1231, 
including 1015 athletes and 
92 coaches & managers).  
 
67% male-  
 
 
*Cross-sectional 
*Questionnaire 
and interview 
*Bespoke self-
report design  
 
 21% of doctors believed that doping 
practices can enhance athletic performance. 
 20% of technicians (which included the 
doctor sample) believed that anabolic 
steroids were frequently used by top level 
athletes. 
 
Greenway and 
Greenway  
(1997) 
 
UK 157 GPs 
Response Rate=39% 
 
*Cross-sectional 
*Questionnaire  
*Bespoke self-
report design 
 
 Only 35% of respondents were aware that 
guidelines on prohibited substance use 
could be found in the BNF. 
 18% had either prescribed or been asked to 
prescribe anabolic steroids for performance 
enhancement or body image purposes.   
 
Laure et al., 
(2000) 
 
France 198 Retail Pharmacists. 
52% male 
Mean age=43 years 
 
Response Rate= 66% 
*Cross-sectional 
*Telephone 
interview 
*Bespoke self-
report design 
 25% had been asked for doping information 
in the previous 12 months.   
 88% considered doping as a public health 
problem and 69% that doping is a form of 
drug addiction.   
 91% of pharmacists believed that they have 
a role to play in doping prevention, but 74% 
considered themselves poorly trained to do 
so.   
 
Laure et al., 
(2003) 
 
 
 
France 
 
202 GPs 
 
76% male 
Mean age=45 years 
 
Response Rate= 51%  
 
*Cross-sectional 
*Telephone 
interview 
*Bespoke self-
report design 
 
 37% had been asked for information and 
11% for a doping prescription in the last 12 
months.   
 89% of GPs believed that they had a role to 
play in preventing doping, but 77% 
considered themselves poorly informed on 
this matter.   
 
 
Panagiotis et 
al., (2006) 
 
Greece 
 
123 trainee GPs 
 
83% male 
Mean age=28 years 
 
Response Rate=100% 
 
 
*Cross-sectional 
questionnaire 
 *Bespoke self-
report design 
 
 Only 25% of respondents knew of the 
WADA/IOC banned list. Only 5.7% correctly 
answered questions on laboratory control 
procedures. 
 99% cited newspapers as their main source 
of doping knowledge. 
 
     
Woods and 
Moynihan 
(2009) 
Ireland 771 GPs  
 
63% male 
Mean age = 46 years. 
 
37% response rate.  
*Cross-sectional 
questionnaire 
*Bespoke self-
report design 
 24% were connected with a specific sport as 
a team doctor/advisor and 28% had been 
consulted for advice on doping in sport. 
12% indicated they had received a request 
for AAS from a coach or an athlete without 
medical indications.  
 92% believed that GPs had a role to play in 
doping prevention; only 9% felt adequately 
trained for this role. 
 
 
Contact with doping 
The studies indicate that it is not uncommon for medical practitioners to receive 
enquiries about, or consult with known users of, doping agents. Laure et al. (2003) reported 
that 37% of respondents had been confronted with doping and Woods and Moynihan (2009) 
stated that 28% of GPs in their Irish study confirmed having been consulted for advice on 
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doping in sport. Moreover, 12% indicated they had received a request for anabolic 
androgenic steroids from coaches or athletes without medical indications. A further 6% of the 
overall sample had received requests for other performance enhancing substances without 
medical indications.  Exposure rates were lower for retail pharmacists - 25% had been 
contacted for information in the previous 12 months (Laure & Kriebitzsch-Lejeune, 2000). 
However, it is not clear from the research who initiated these ‘contacts’. Pharmacists (6%) 
also reported being offered financial or other incentives to supply doping agents to athletes in 
the last 12 months (Laure & Kriebitzsch-Lejeune, 2000).  
 
Training and knowledge of doping 
Medical practitioners have limited doping agent knowledge and this may influence their 
actions when solicited for such advice. In the studies reviewed, knowledge was assessed by 
variously identifying substances on the Prohibited List, estimating substance efficacy, and 
identifying either health effects and/or sanctions. Assessment of the classes of prohibited 
substances was the only knowledge constituent to unite all these studies. Even then, there 
were inconsistencies in whether actual or perceived knowledge of the Prohibited List was 
examined.  
Regarding specific knowledge about prohibited substances, Panagiotis et al. (2006)  
reported that only 25% of Greek trainee GPs had heard of the current List of Prohibited 
Substances. This finding is broadly consistent with an earlier study by Greenway and 
Greenway (1997) who noted only one third of UK GPs were aware of the prohibited 
substances in sport list readily available in the British National Formulary (BNF). Most 
recently, Woods and Moynihan found that knowledge of drug-testing procedures was 
reported by 25% of their Irish sample (24% of this sample of 771 was formally connected 
with a specific sport as a team doctor/advisor); Panagiotis and colleagues (2006) found that 
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fewer than 6% of the trainees had knowledge of correct laboratory procedures for doping 
tests. Greenway and Greenway (1997) found that 12% of UK GPs thought that doctors were 
permitted to prescribe anabolic steroids for non-medical purposes and 17% did not know; in 
the United Kingdom this non-medical prescription is not permitted (Greenway & Greenway, 
1997).  
 In terms of anti-doping education, Laure et al. (2003) found 77% of French GPs 
considered they were poorly trained in this area. In the most recent study (Woods & 
Moynihan, 2009) only 9% of Irish GPs surveyed felt adequately trained in the prevention of 
doping in sport and 86% felt that further training in relation to doping issues was required. A 
discrepancy emerged between the 24% of respondents who reported being connected with a 
sport as a team doctor or advisor and the 12% of GPs who had completed specific training on 
doping in sport. Having said this, 12% of Irish GPs stated they did not feel further training 
was necessary and qualified that the investment of their time in training on this issue would 
be disproportionate to their exposure to this issue.  
 
Attitudes towards doping 
Cross-sectional designs and bespoke survey instruments characterised the survey 
studies included in this review. Idiosyncratic survey design is problematic when assessing 
attitudes towards doping because of the need for psychometric rigour in designing such 
questionnaires. This challenge may help to understand the general lack of available research 
on attitudes towards doping in medical practitioners. However, Laure et al. (2000) noted 88% 
of French pharmacists considered doping to be a public health problem, with the majority 
regarding it as a form of addiction. Woods and Moynihan (2009) also reported that in the 
event of an athlete insisting on taking a prohibited substance, 90% of GPs would discourage 
the use of the substances in all circumstances.  
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Current prevention methods 
There was general agreement that more frequent and efficacious doping control is 
required. However, prevention appears to be at the heart of the intervention approaches. 
Laure et al. (2003) found that 81% of French GPs believed that doping prevention was 
important because of the health risks associated with such practices and 12% endorsed 
prevention to support sporting ethics. In an earlier study, 73% of pharmacists considered 
current prevention methods to be ineffective (Laure & Kriebitzsch-Lejeune, 2000). More 
recently (Panagiotis, et al., 2006) 48% of trainee GPs considered that contemporary 
prevention methods were ineffective. Deeper investigations into prevention showed that the 
majority of French GPs (55%) (Laure, et al., 2003) believed that prevention efforts should be 
aimed primarily at children and adolescents, with less priority afforded to professional and 
amateur athletes (Laure, et al., 2003). 
 
Discussion 
This review examined the scale, range and consensus in the extant literature of a diffuse 
range of medical practitioners’ knowledge of, attitudes towards and beliefs regarding doping 
in sport. A fragmented landscape has emerged, based on studies across 20 years.  This shows 
only few studies, all of European origin, and all featuring bespoke assessment tools 
developed to answer a wide variety of isolated research questions. What was common to the 
studies was a focus on PEDs within sport, rather than recreational use by athletes. In sum, 
this literature may be best regarded as providing practice-based evidence of anti-doping for 
sport enhancement, reflecting different contexts of legislation, speed of change and policy 
development.  
Owing to this narrow evidence base, caution must be taken when attempting to 
generalise the findings of the individual papers to the wider medical professional community. 
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These limitations notwithstanding, a negative attitude towards doping in sport prevails but 
this is combined with a lack of doping knowledge, a feeling of insufficient anti-doping 
training and a limited confidence in current prevention efforts. 
Taken together, the broad sweep of the evidence suggests a need to review medical 
professionals’ education and professional development in relation to doping in sport. Speed 
and Jaques (2010) refer to the Sports Physician as a ‘medical guardian’ and they specifically 
highlight that they ‘work hard to ensure that the athlete understands and adheres to anti-
doping codes’ (p. 2). However, a lack of knowledge and understanding of anti-doping 
governance on the part of the medical guardian could lead to misinformed practice. 
Ultimately, this presents the possibility of a sanction under the 2009 World Anti-Doping 
Agency Code (WADC) for both the athlete and medical practitioner. However, WADA has 
no jurisdiction to punish medical practitioners. Therefore, sanctioning practitioners in breach 
of the WADC remains with the relevant sports bodies (McNamee & Phillips, 2010). WADA 
recommends that offending practitioners are banned from working with athletes within that 
sporting body (McNamee & Phillips, 2010). 
Supporting the findings of doping attitude surveys of elite athletes (Alaranta, et al., 
2006; Anshel, 1991) the studies reviewed here suggests a widespread anti-doping attitude 
stance. Indeed, the most recent investigation found that an overwhelming majority of GPs 
would discourage an athlete’s use of a prohibited substance even if the athlete insisted on 
continued use (Woods & Moynihan, 2009). Having said this, professional variability was 
highlighted by the minority of GPs who confirmed that they would prescribe or supply the 
requested agent. Moreover, a number of respondents chose not to answer the question (8%) 
and almost one in four respondents was ready to refer the athlete to another doctor for 
prescription and monitoring. Whilst no explanations were sought or offered for such decision 
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making, the inter-individual variability observed is akin to prescribing in the wider medical 
literature.  
Medical practitioners differ from one another in their communicative behaviour; some 
have a more patient-centred style and others less so (Zandbelt, Smets, Oort, Godfried, & de 
Haes, 2006). Such inter-individual variability suggests that while some medical practitioners 
may be bastions of doping prevention, others may be prepared to consider providing illegal 
performance enhancing substances as part of their patient care regime. In the case of the 
BALCO scandal, practitioners facilitated doping practices (Fainaru-Wada & Williams, 2006). 
In stark contrast, the East German doping programme involved  doping athletes without their 
consent (Werner & Berendonk, 1997). Thus, the medical practitioners’ rationale for 
providing this context is worthy of closer inspection. However, the complexity of the 
situation should not be discounted when considering the interaction of this professional body, 
who often offer their time freely, with the anti-doping landscape. On the one hand medical 
practitioners are expected to stay abreast of evidence and apply the latest technologies in the 
pursuit of performance enhancement and on the other hand they are expected to be sensitive 
caregivers and remain within the realms of prescribing regulations. Therefore, we must 
recognise and explore the tensions which can emerge from a pressure to fulfil such multiple 
roles (Cassell, 1991); neither can the concepts of confidentiality and disclosure be overlooked 
(McNamee & Phillips, 2010). Furthermore, recognition must be made of the dual obligations 
in this group; these may arise due to professional obligations to patients alongside obligations 
to sports clubs or associations to which they are contracted.  
The literature suggests that a low level of doping knowledge exists in the practitioner 
groups surveyed and this resonated as cause for concern across a number of studies. Yet, 
none of the studies linked knowledge to engagement within sport (as a medical practitioner) 
which could extend from the local GP who receives a visit from a young athlete with a cold 
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to the salaried sports medic who resides with the athlete or team. The depth of knowledge 
required for these two medical professionals is arguably different and therefore presents a 
challenge for anti-doping education bodies. Woods and Moynihan (2009) reported that 24% 
of their Irish GP sample were employed by a sport on a permanent or ad-hoc basis, yet, only 
half of that group reported receiving appropriate training in anti-doping. This is a concerning 
statistic given the potential for an accidental breach of doping regulations as it is not 
uncommon for athletes to be unknowingly prescribed banned medical agents (Webborn, 
1997). 
Current anti-doping legislation may be seen as playing out against medical 
practitioners’ strong sense of personal autonomy and it may be argued that it contravenes the 
ethos of patient-centeredness. Paradoxically, where an athlete presents a desire to use a 
prohibited substance (for whatever reason), it may be patient-advantageous to display less 
patient-centred behaviours given the implications for both parties of a positive dope test in 
international sport. However, the importance of respecting patient autonomy is underscored 
in the general medical literature (Quill & Brody, 1996) and this aligns with the argument that 
the non-medical experimentation of illegal performance enhancing substances is a matter of 
individual choice (Kennedy & Kennedy, 1999). Yet, these perspectives are at odds with 
current anti-doping regulations and the GMC Standards Committee holds a very clear view 
that doctors will contravene the guidance by prescribing or colluding in the provision of 
drugs or treatment with the intention of improperly enhancing an individual’s performance in 
sport. The GMC state that such actions would usually raise a question of a doctor’s continued 
registration (BMA, 2001). Whilst the study by Woods and Moynihan (2009) has highlighted 
some of the different approaches taken by GPs when faced with a doping athlete, the 
intricacies of the decision making process, involving such a doping dilemma, is worthy of 
further consideration. 
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The six reviewed studies examined medical practitioners from across Europe using 
cross-sectional designs. Notwithstanding their similar research designs, the survey 
instruments utilised are defined by their disparate style making cross-study comparisons 
difficult. While definitive conclusions cannot be drawn, the outcomes from this review 
remain important for developing a more robust and coherent future for research in this field. 
Firstly, the span and scale of the evidence base needs to be developed to generate a solid 
foundation from which to inform policy and practice. Given the potential complexity in this 
field, it would be wise to follow the guidance of Rutter and colleagues (2001) and adopt a 
systematic approach that generates knowledge from converging evidence, delivering it 
through multiple research strategies and methods. Taking into consideration the infancy of 
this research, it is to be expected that cross-sectional designs will continue to be favoured 
albeit with refinements that make the outcomes more informative. At the same time, 
researchers are encouraged to supplement this mode of data acquisition with qualitative 
methods and experimental approaches to generate data convergence. This offers a chance of 
ensuring relevance and contribution of research in this domain to daily routines and practice.  
This review flags the inherent challenges facing medical practitioners who operate in a 
complex anti-doping landscape. Looking forward, a specific focus on those who specialise in 
Sport and Exercise Medicine appears justified as they may regularly (if not frequently) 
encounter doping issues. Alongside this target audience for the research, the issue of source 
credibility is worthy of closer inspection given that existing literature questions their 
credibility among some ‘patient’ groups. For example, anabolic androgenic steroid users have 
been reluctant to engage with medical professionals in relation to their AAS use (Dawson, 
2001). Kanayama et al. (2010) suggests this may be due to the historical reluctance of the 
science and medicine community to recognise the efficacy of AAS use. 
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This current review has also exposed dissatisfaction with contemporary prevention 
methods’ effectiveness. This, together with the common conviction that medical practitioners 
have a role to play in future initiatives, suggests that professional bodies should be more fully 
engaged in this complex issue. The importance of examining continued professional 
development is also underscored by the fact that the WADC is dynamic, meaning that those 
affected by Code compliance must keep abreast of the field.  Having said this, it would be 
timely to establish the position of the medical body in relation to the comparative importance 
of receiving education on this issue relative to other training needs and practitioner pressures. 
This question could even be part of the annual review process for general practitioners.  
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